This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

15 Feb 2011

Lucentis Phase III Study for DME Meets Goals

Genentech, Inc., a member of the Roche Group, said the RISE study evaluating monthly Lucentis in patients with diabetic macular edema (DME), met its primary endpoint.

Genentech announced yesterday that its Phase III study evaluating monthly Lucentis (ranibizumab injection) in patients with diabetic macular edema (DME), met its goals.


DME is a serious complication of diabetes that can lead to blurred vision, severe vision loss and blindness. The RISE study showed that a significantly higher percentage of patients receiving monthly Lucentis achieved an improvement in vision of at least 15 letters on the eye chart at 24 months, compared to placebo. A preliminary analysis of the data did not reveal any unexpected safety signals.


“DME is a leading cause of blindness among working-aged adults in most developed countries, and currently t

Related News